VistaGen Therapeutics Overview

  • Founded
  • 1998
Founded
  • Status
  • Public
  • Employees
  • 11
Employees
  • Stock Symbol
  • VTGN
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $2.62
  • (As of Thursday Closing)

VistaGen Therapeutics General Information

Description

VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 343 Allerton Avenue
  • South San Francisco, CA 94080
  • United States
+1 (650) 000-0000

VistaGen Therapeutics Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

VistaGen Therapeutics Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.62 $2.66 $0.35 - $3.18 $498M 190M 3.07M -$0.26

VistaGen Therapeutics Financials Summary

In Thousands,
USD
TTM 31-Dec-2020 FY 2020 31-Mar-2020 FY 2019 31-Mar-2019 FY 2018 31-Mar-2018
EV 255,015 24,772 46,412 8,280
Revenue 648 0 0 0
EBITDA (14,876) (20,698) (24,488) (14,254)
Net Income (14,990) (20,774) (24,590) (14,346)
Total Assets 109,271 5,772 14,012 11,278
Total Debt 3,901 4,092 67 66
Public Fundamental Data provided by Morningstar, Inc. disclaimer

VistaGen Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore VistaGen Therapeutics‘s full profile, request access.

Request a free trial

VistaGen Therapeutics Executive Team (7)

Name Title Board Seat Contact Info
Shawn Singh JD Chief Executive Officer & Board Member
Jerrold Dotson Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
H. Snodgrass Co-Founder, President, Chief Scientific Officer & Board Member
Gordon Keller Co-Founder
Mark McPartland Vice President
You’re viewing 5 of 7 executive team members. Get the full list »

VistaGen Therapeutics Board Members (4)

Name Representing Role Since
00000 000000000 00.0 VistaGen Therapeutics Director 000 0000
0. 000000000 VistaGen Therapeutics Co-Founder, President, Chief Scientific Officer & Board Member 000 0000
0000 0000 00 Self Chairman 000 0000
00000 00000 00 VistaGen Therapeutics Chief Executive Officer & Board Member 000 0000
To view VistaGen Therapeutics’s complete board members history, request access »

VistaGen Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

VistaGen Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore VistaGen Therapeutics‘s full profile, request access.

Request a free trial

VistaGen Therapeutics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 00000000 11-May-2011 000000000000000000 Other Consumer Products and Services 00000 00000 00
To view VistaGen Therapeutics’s complete acquisitions history, request access »